Novavax Announces Adjustment of Conversion Rate for its 3.75% Convertible Senior Notes due 2023


GAITHERSBURG, Md., May 10, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced an adjustment to the conversion rate applicable to its existing 3.75% Convertible Senior Notes due 2023 (Notes), pursuant to that certain Indenture between Novavax and The Bank of New York Mellon Trust Company, N.A., as trustee (Indenture), effective May 10, 2019.

As approved by Novavax’ stockholders at a special meeting held on May 8, 2019, Novavax effected a reverse stock split of its issued and outstanding common stock, par value $0.01 (Common Stock) at a ratio of 1-for-20, effective as of 12:01 a.m. Eastern Time on May 10, 2019 (Reverse Stock Split).

As a result of the Reverse Stock Split and pursuant to Section 14.04(a) of the Indenture, effective May 10, 2019, the conversation rate under the Indenture will be equal to 7.3411 shares of Common Stock per $1,000 principal amount of the Convertible Notes.

As a result of the foregoing adjustment to the conversion rate and pursuant to Section 14.03(d) of the Indenture, effective May 10, 2019, the table setting forth the number of additional shares of Common Stock to be added to the conversion rate for each $1,000 principal amount of Notes in connection with a make-whole adjustment event based on hypothetical stock prices and effective dates pursuant to Section 14.03(e) of the Indenture was adjusted to read as follows:

    Stock Price
Effective Date   $ 111.20   $ 120.00   $ 130.00   $ 136.20   $ 140.00   $ 160.00   $ 200.00   $ 300.00   $ 400.00   $ 500.00   $ 600.00
January 29, 2016   1.6517   1.5755   1.3668   1.2563   1.1952   0.9315   0.5983   0.2342   0.0979   0.0373   0.0093
February 1, 2017   1.6517   1.6068   1.3859   1.2695   1.2053   0.9302   0.5881   0.2242   0.0918   0.0341   0.0079
February 1, 2018   1.6517   1.6198   1.3862   1.2639   1.1967   0.9113   0.5636   0.2069   0.0823   0.0292   0.0057
February 1, 2019   1.6517   1.6311   1.3803   1.2501   1.1789   0.8802   0.5267   0.1830   0.0697   0.0231   0.0032
February 1, 2020   1.6517   1.6055   1.3357   1.1972   1.1221   0.8124   0.4616   0.1478   0.0530   0.0156   0.0007
February 1, 2021   1.6517   1.5419   1.2458   1.0966   1.0167   0.6962   0.3602   0.1017   0.0341   0.0081   0.0000
February 1, 2022   1.6517   1.3911   1.0532   0.8889   0.8030   0.4796   0.1974   0.0475   0.0157   0.0019   0.0000
February 1, 2023   1.6517   0.9923   0.3512   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000   0.0000

About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a late-stage biotechnology company that drives improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Its two priority programs are ResVax™, its RSV vaccine for infants via maternal immunization, and NanoFlu™, its quadrivalent influenza nanoparticle vaccine. Novavax’ proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic nanoparticles addressing urgent global health needs.

For more information, visit and connect with us on Twitter and LinkedIn.


Novavax, Inc.
Erika Trahan
Senior Manager, Investor & Public Relations

Westwicke Partners
John Woolford 443-213-0506

About GlobeNewswire

One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

SDRL – Seadrill Limited Announces Contract Award for the West Gemini17.7.2019 22:35:00 CESTPress release

Hamilton, Bermuda, July 17, 2019 - Seadrill Limited ("Seadrill" or "the Company") has secured a nine well contract with three options, each for two wells, for the West Gemini in West Africa. Total contract value for the firm portion of the contract is expected to be approximately $84 million with commencement expected in early Q4 2019 and running through Q4 2020. FORWARD LOOKING STATEMENTS This news release includes forward looking statements. Such statements are generally not historical in nature, and specifically include statements about the Company's plans, strategies, business prospects, changes and trends in its business, the markets in which it operates and its restructuring efforts. These statements are made based upon management's current plans, expectations, assumptions and beliefs concerning future events impacting the Company and therefore involve a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed or imp

GrandVision confirms HAL and EssilorLuxotica are engaged in discussions on a possible sale of controlling interest of HAL in GrandVision17.7.2019 18:45:00 CESTPress release

Schiphol, The Netherlands - 17 July 2019. GrandVision NV (Euronext: GVNV) confirms that it has been approached by EssilorLuxottica SA (Euronext: EL) and HAL Holding NV (Euronext: HAL) in connection with a possible sale of HAL’s 76.72% ownership interest in GrandVision to EssilorLuxottica at an envisaged purchase price per share of approximately EUR28.00. At this stage it is uncertain whether an agreement between EssilorLuxottica and HAL will be reached. While a transaction would be between HAL and EssilorLuxottica, GrandVision’s support has been requested. Completion of a sale of HAL’s ownership interest in GrandVision would be subject to customary conditions including approval from relevant regulatory authorities in various jurisdictions, which may take between 12 and 24 months. Following completion of the transaction between HAL and EssilorLuxottica, EssilorLuxottica will make a (mandatory) public offer for all shares in GrandVision. Further announcements will be made if and when req

Solutions 30 : 79.8% revenue growth in the first half of 201917.7.2019 18:00:00 CESTPress release

79.8% revenue growth in the first half of 2019 France: revenue up 74.4% Other countries: revenue up 90.3% Reliable, cash-generating model Solutions 30 SE, the European leader in solutions for new technologies, today disclosed its revenue for the first half of 2019 . In millions of euros (Unaudited figures) HY Q2 2019 2018 % change 2019 2018 % change Total 317.8 176.7 +79.8% 157.4 91.5 +72.1% From France 202.8 116.3 +74.4% 101.5 59.5 +70.6% From other countries 115.0 60.4 +90.3% 55.9 32.0 +74.7% Sustained growth trend continues Solutions 30 maintains its high growth trajectory, disclosing revenues of €317.8 million for the first half of 2019, a 79.8% increase (36.9% of which was organic growth1). For the 2nd quarter alone, revenue increased by 72.1%, reaching €157.4 million. Organic growth represented 32.3%. The group continues to demonstrate the relevance of its positioning and strategy in markets driven by the economy’s digital transformation and major technology groups’ outsourcing o

ObsEva Hosts KOL Meeting on IVF Trends, Unmet Need and Market Potential of Nolasiban17.7.2019 18:00:00 CESTPress release

Company remains on track to submit Nolasiban MAA in the fourth quarter of 2019 GENEVA, Switzerland and BOSTON, MA - July 17, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today hosted a key opinion leader (KOL) meeting in New York City on in-vitro fertilization (IVF). At the event, three KOLs in women’s reproductive health along with company executives discussed trends in IVF, including current practice trends toward Day 5 embryo transfer, and the merits of single-embryo transfer (SET) vs. double embryo transfer (DET). Further, event participants discussed the potential clinical importance of nolasiban, ObsEva’s oral oxytocin receptor antagonist, to significantly improve the live birth rate (LBR) resulting from ET, and address the high physical, emotional and financial pain associated with fa

Bizagi goes from Stealth to Hyper Growth Delivering Digital Transformation for World Leading Brands17.7.2019 18:00:00 CESTPress release

From Adidas and Audi to Ikea and the U.S. government, Bizagi’s unique Intelligent Process Automation helping organizations harness the power of RPA and AI to speed transformation SANTA CLARA, Calif., July 17, 2019 (GLOBE NEWSWIRE) -- Bizagi, the world’s leading Intelligent Process Automation platform provider, today announced significant growth in the U.S. and abroad driven by its success enabling digital transformation for world leading brands such as DHL, Gap, Citizens Bank, AON and numerous U.S. government agencies including the Departments of Agriculture, Defense, Energy, HHS, Homeland Security and many others. Bizagi’s growth is based on enterprise adoption of its unique Intelligent Process Automation, enabling companies to better leverage digital and robotic processes, along with artificial intelligence, to improve customer interaction, speed operations and build revenue. This news follows the company’s recognition last month as a leader in The Forrester Wave™: Software for Digit

EnBW International Finance B.V.: Half-yearly report17.7.2019 17:00:00 CESTPress release

EnBW International Finance B.V.: Half-yearly report 2019 In accordance with the Transparency Directive (Directive 2004/109/EC), as amended by the Transparency Directive Amending Directive (Directive 2013/50/EU), and following the choice of EnBW International Finance B.V. for The Netherlands as Home Member State, EnBW International Finance B.V. hereby informs that the half-year financial reports for the period 1 January 2019 till 30 June 2019 have been filed on 17 July 2019 with the Autoriteit Financiële Markten (AFM) in The Netherlands and are available on the internet site: